TrialJournal of diabetes science and technology2015

Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.

Ken Fujioka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.